Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat versus best available therapy in relapsed/refractory high-risk myelofibrosis after JAK inhibitor treatment
2023-509120-17-00Phase 3Authorised
- Sponsor
- Geron Corporation
- Start
- Apr 2021
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 27
01
Overview
Phase 3, randomised, open-label trial of imetelstat in myelofibrosis (MF) (2 arms), sponsored by Geron Corporation. Primary endpoint: Overall survival. Planned start Apr 2021; status: authorised.
02
Drugs
imetelstat
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2023-509120-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509120-17-00.